Ultragenyx Pharmaceutical, Inc. (RARE)

Ultragenyx Pharmaceutical Inc. stock has been impacted by several key events in the past six months. The company reported a wider-than-expected loss in Q1 2026, but the stock increased as investors focused on reaffirmed revenue guidance and the path to profitability. The company reported losses in Q4 2025 and Q3 2025. Upcoming FDA PDUFA action dates for DTX401 and UX111 are significant catalysts. Phase 3 data for GTX-102 is expected in the second half of 2026. As of May 7, 2026, the stock was trading at $26.15, with a year-to-date increase of 13.6%, but a 12-month decrease of 27.38%.

Demand seasonality has been noted for Crysvita, with first-quarter revenues in 2026 consistent with expected seasonality in the U.S. and Canada, as well as ordering patterns in Brazil.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on researching and developing novel treatments for rare and ultra-rare genetic diseases. The company operates in the Biotechnology and Life Sciences sector, utilizing drug modalities like biologics, small molecules, gene therapies, and ASO and mRNA technologies. Its approved products include Burosumab (Crysvita) for XLH and TIO, Triheptanoin (Dojolvi) for LC-FAOD, Vestronidase alfa (Mepsevii) for MPS VII, and Evinacumab-dgnb (Evkeeza) for HoFH. The company also has a clinical-stage pipeline with investigational therapies for diseases like GSDIa, OTC, Osteogenesis Imperfecta, Angelman syndrome, Wilson disease, and GNE myopathy.

Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California, with additional presences in Brisbane, California, and the Boston area. Its Latin American headquarters is located in Miami. Globally, Ultragenyx has offices and laboratories in 12 countries across North America, Europe, Asia, and Latin America, and its therapies are approved and sold in over 26 countries, including Canada, Latin America, Europe, and Japan.

Ultragenyx has maintained a positive brand reputation, emphasizing its commitment to rare disease innovation and patient communities. The company released its 2024 Impact Report, supports the rare disease community through initiatives like its "Rare Bootcamp," and engages in "Global Days of Service." Ultragenyx elevated awareness for Rare Disease Day and contributed to non-profit organizations. The company has been recognized for its growth and as a desirable workplace.

Ultragenyx Pharmaceutical Inc. is predominantly owned by institutional investors, holding over 95% of outstanding shares, including Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The largest individual insider shareholder is Dr. Emil Kakkis, the company's President, CEO, and Chairman. Insider selling has exceeded buying in the past three months.